EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis

Allergic rhinoconjunctivitis (AR) is an allergic disorder of the nose and eyes affecting about a fifth of the general population. Symptoms of AR can be controlled with allergen avoidance measures and pharmacotherapy. However, many patients continue to have ongoing symptoms and an impaired quality of life; pharmacotherapy may also induce some side‐effects. Allergen immunotherapy (AIT) represents the only currently available treatment that targets the underlying pathophysiology, and it may have a disease‐modifying effect. Either the subcutaneous (SCIT) or sublingual (SLIT) routes may be used. This Guideline has been prepared by the European Academy of Allergy and Clinical Immunology's (EAACI) Taskforce on AIT for AR and is part of the EAACI presidential project “EAACI Guidelines on Allergen Immunotherapy.” It aims to provide evidence‐based clinical recommendations and has been informed by a formal systematic review and meta‐analysis. Its generation has followed the Appraisal of Guidelines for Research and Evaluation (AGREE II) approach. The process included involvement of the full range of stakeholders. In general, broad evidence for the clinical efficacy of AIT for AR exists but a product‐specific evaluation of evidence is recommended. In general, SCIT and SLIT are recommended for both seasonal and perennial AR for its short‐term benefit. The strongest evidence for long‐term benefit is documented for grass AIT (especially for the grass tablets) where long‐term benefit is seen. To achieve long‐term efficacy, it is recommended that a minimum of 3 years of therapy is used. Many gaps in the evidence base exist, particularly around long‐term benefit and use in children.

[1]  A. Sheikh,et al.  Challenges in the implementation of the EAACI AIT guidelines: A situational analysis of current provision of allergen immunotherapy , 2018, Allergy.

[2]  A. Sheikh,et al.  Health economic analysis of allergen immunotherapy for the management of allergic rhinitis, asthma, food allergy and venom allergy: A systematic overview , 2018, Allergy.

[3]  A. Sheikh,et al.  Challenges in the implementation of EAACI guidelines on allergen immunotherapy: A global perspective on the regulation of allergen products , 2018, Allergy.

[4]  A. Sheikh,et al.  EAACI guidelines on allergen immunotherapy: Prevention of allergy , 2017, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[5]  P Demoly,et al.  Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper , 2017, Allergy.

[6]  E. Valovirta,et al.  Results from the 5‐year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy , 2017, The Journal of allergy and clinical immunology.

[7]  K. Okubo,et al.  Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite–induced allergic rhinitis , 2017, The Journal of allergy and clinical immunology.

[8]  S. Durham,et al.  Intradermal grass pollen immunotherapy increases TH2 and IgE responses and worsens respiratory allergic symptoms , 2017, The Journal of allergy and clinical immunology.

[9]  A. Sheikh,et al.  Allergen immunotherapy for allergic asthma: A systematic review and meta‐analysis , 2017, Allergy.

[10]  A. Sheikh,et al.  Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta‐analysis , 2017, Allergy.

[11]  P. Demoly,et al.  European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): a real‐life clinical assessment , 2017, Allergy.

[12]  A. Togias,et al.  Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on Nasal Response to Allergen Challenge at 3 Years Among Patients With Moderate to Severe Seasonal Allergic Rhinitis: The GRASS Randomized Clinical Trial , 2017, JAMA.

[13]  P. Demoly,et al.  The European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): A paediatric assessment , 2017, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[14]  A. Sheikh,et al.  Allergen immunotherapy for the prevention of allergy: A systematic review and meta‐analysis , 2017, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[15]  D. Bernstein,et al.  Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial. , 2016, The Journal of allergy and clinical immunology.

[16]  T. Reinhold,et al.  Cost-effectiveness of grass pollen SCIT compared with SLIT and symptomatic treatment , 2016, Allergo Journal International.

[17]  S. Durham,et al.  Pathogenesis of rhinitis , 2016, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[18]  R. Valenta,et al.  Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy , 2016, EBioMedicine.

[19]  F. Spertini,et al.  Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study. , 2016, The Journal of allergy and clinical immunology.

[20]  Z. Patel,et al.  Immunotherapy compliance: comparison of subcutaneous versus sublingual immunotherapy , 2016, International forum of allergy & rhinology.

[21]  J. Virchow,et al.  Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial. , 2016, JAMA.

[22]  G. Liss,et al.  Risk factors for fatal and nonfatal reactions to subcutaneous immunotherapy: National surveillance study on allergen immunotherapy (2008-2013). , 2016, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[23]  A. Sheikh,et al.  Allergen immunotherapy for allergic rhinoconjunctivitis: protocol for a systematic review , 2016, Clinical and Translational Allergy.

[24]  V. Backer,et al.  Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial. , 2016, The Journal of allergy and clinical immunology.

[25]  A. Bonny,et al.  Three-injection intralymphatic immunotherapy in adolescents and young adults with grass pollen rhinoconjunctivitis. , 2016, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[26]  A. Bozek,et al.  Pre-seasonal, subcutaneous immunotherapy: a double-blinded, placebo-controlled study in elderly patients with an allergy to grass. , 2016, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[27]  R. Van Ree,et al.  International Consensus on Allergen Immunotherapy II: Mechanisms, standardization, and pharmacoeconomics. , 2016, The Journal of allergy and clinical immunology.

[28]  P. Demoly,et al.  Management of the polyallergic patient with allergy immunotherapy: a practice-based approach , 2016, Allergy, Asthma & Clinical Immunology.

[29]  Z. Lin,et al.  The effects of house dust mite sublingual immunotherapy in patients with allergic rhinitis according to duration , 2016, International forum of allergy & rhinology.

[30]  Paul Oykhman,et al.  Allergen immunotherapy in pregnancy , 2015, Allergy, Asthma & Clinical Immunology.

[31]  C. Bachert,et al.  Allergen immunotherapy on the way to product-based evaluation—a WAO statement , 2015, The World Allergy Organization journal.

[32]  R. Vaswani,et al.  Non-adherence to subcutaneous allergen immunotherapy: inadequate health insurance coverage is the leading cause. , 2015, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[33]  R. Van Ree,et al.  International consensus on allergy immunotherapy. , 2015, The Journal of allergy and clinical immunology.

[34]  Kayleigh Kew,et al.  Best of the Other Journals , 2021, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[35]  P. Demoly,et al.  Clinical contraindications to allergen immunotherapy: an EAACI position paper , 2015, Allergy.

[36]  H. Malling,et al.  Prolonged efficacy of the 300IR 5-grass pollen tablet up to 2 years after treatment cessation, as measured by a recommended daily combined score , 2015, Clinical and Translational Allergy.

[37]  P. Gevaert,et al.  Local IgE in non‐allergic rhinitis , 2015, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[38]  R. Valenta,et al.  Mold Allergens in Respiratory Allergy: From Structure to Therapy , 2015, Allergy, asthma & immunology research.

[39]  M. Calderón,et al.  Network meta-analysis shows commercialized subcutaneous and sublingual grass products have comparable efficacy. , 2015, The journal of allergy and clinical immunology. In practice.

[40]  V. Backer,et al.  SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms. , 2015, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[41]  B. García,et al.  Optimal duration of allergen immunotherapy in children with dust mite respiratory allergy , 2015, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[42]  M. Augustin,et al.  Health economic comparison of SLIT allergen and SCIT allergoid immunotherapy in patients with seasonal grass-allergic rhinoconjunctivitis in Germany , 2015, Clinical and Translational Allergy.

[43]  H. Sitter,et al.  Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases , 2014, Allergo Journal International.

[44]  S. Thum-Oltmer,et al.  Patients’ compliance with different administration routes for allergen immunotherapy in Germany , 2014, Patient preference and adherence.

[45]  L. Klimek,et al.  A high polymerized grass pollen extract is efficacious and safe in a randomized double-blind, placebo-controlled study using a novel up-dosing cluster-protocol , 2014, Allergy.

[46]  A. Bozek,et al.  Grass Pollen Sublingual Immunotherapy: A Double-Blind, Placebo-Controlled Study in Elderly Patients with Seasonal Allergic Rhinitis , 2014, American journal of rhinology & allergy.

[47]  G. Canonica,et al.  Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. , 2014, The Journal of allergy and clinical immunology.

[48]  P. Demoly,et al.  Rhinitis , sinusitis , and upper airway disease Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis , 2016 .

[49]  G. Ciprandi,et al.  Types of sensitization to aeroallergens: definitions, prevalences and impact on the diagnosis and treatment of allergic respiratory disease , 2014, Clinical and Translational Allergy.

[50]  S. Durham,et al.  Dropouts in sublingual allergen immunotherapy trials – a systematic review , 2014, Allergy.

[51]  S. Ronaldson,et al.  Economic evaluation of SQ-standardized grass allergy immunotherapy tablet (Grazax®) in children , 2014, ClinicoEconomics and outcomes research : CEOR.

[52]  J. Bousquet,et al.  Sublingual immunotherapy: World Allergy Organization position paper 2013 update , 2014, The World Allergy Organization journal.

[53]  Lanfang Cao,et al.  Efficacy and Safety of Sublingual Immunotherapy in Children Aged 3–13 Years with Allergic Rhinitis , 2014, American journal of rhinology & allergy.

[54]  D. Larenas-Linnemann,et al.  Use of omalizumab to improve desensitization safety in allergen immunotherapy. , 2014, The Journal of allergy and clinical immunology.

[55]  Joaquín Sánchez,et al.  Safety of immunotherapy in patients with rhinitis, asthma or atopic dermatitis using an ultra-rush buildup. A retrospective study. , 2014, Allergologia et immunopathologia.

[56]  H. Malling,et al.  Sustained efficacy and safety of a 300IR daily dose of a sublingual solution of birch pollen allergen extract in adults with allergic rhinoconjunctivitis: results of a double-blind, placebo-controlled study , 2014, Clinical and Translational Allergy.

[57]  T. Khurana,et al.  Comparison Of Total Protein Profile Of Alternaria Alternata Extract Obtained From Various U.S. Allergenic Extract Manufacturers , 2014 .

[58]  P. Patel,et al.  Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen. , 2014, The Journal of allergy and clinical immunology.

[59]  H. Malling,et al.  Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? , 2013, The Journal of allergy and clinical immunology.

[60]  O. Pfaar,et al.  Depigmented–polymerized mixed grass/birch pollen extract immunotherapy is effective in polysensitized patients , 2013, Allergy.

[61]  N. Papadopoulos,et al.  Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology , 2013, Allergy.

[62]  G. Passalacqua,et al.  Causes of SLIT discontinuation and strategies to improve the adherence: a pragmatic approach , 2013, Allergy.

[63]  B. Kaambwa,et al.  A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis. , 2013, Health technology assessment.

[64]  J. Bousquet,et al.  Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. , 2013, The Journal of allergy and clinical immunology.

[65]  T. Casale,et al.  Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults. , 2013, The Journal of allergy and clinical immunology.

[66]  H. Malling,et al.  Post‐treatment efficacy of discontinuous treatment with 300IR 5‐grass pollen sublingual tablet in adults with grass pollen‐induced allergic rhinoconjunctivitis , 2013, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[67]  P. Kuna,et al.  Perennial is more effective than preseasonal subcutaneous immunotherapy in the treatment of seasonal allergic rhinoconjunctivitis , 2013, American journal of rhinology & allergy.

[68]  L. Cox,et al.  Allergy immunotherapy: reduced health care costs in adults and children with allergic rhinitis. , 2013, The Journal of allergy and clinical immunology.

[69]  S. Durham,et al.  Efficacy and safety of the SQ‐standardized grass allergy immunotherapy tablet in mono‐ and polysensitized subjects , 2013, Allergy.

[70]  A. Bozek,et al.  House dust mite sublingual immunotherapy: a double‐blind, placebo‐controlled study in elderly patients with allergic rhinitis , 2013, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[71]  D. Larenas-Linnemann,et al.  Adjuvants for immunotherapy , 2012, Current opinion in allergy and clinical immunology.

[72]  K. Smejda,et al.  Comparison of the long-term efficacy of 3- and 5-year house dust mite allergen immunotherapy. , 2012, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[73]  W. Hop,et al.  Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. , 2012, The Journal of allergy and clinical immunology.

[74]  M. Calderón,et al.  Subcutaneous allergen immunotherapy for allergic disease: examining efficacy, safety and cost-effectiveness of current and novel formulations. , 2012, Immunotherapy.

[75]  Marco A Garcia,et al.  Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy. , 2012, The Journal of allergy and clinical immunology.

[76]  W. Shaikh,et al.  A prospective study on the safety of sublingual immunotherapy in pregnancy , 2012, Allergy.

[77]  L. Hothorn,et al.  Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. , 2012, The Journal of allergy and clinical immunology.

[78]  M. Augustin,et al.  Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany , 2012, Journal of medical economics.

[79]  P. Demoly,et al.  Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile , 2012, Allergy.

[80]  J. Jerzyńska,et al.  Comparative effect of pre‐coseasonal and continuous grass sublingual immunotherapy in children , 2012, Allergy.

[81]  W. Hop,et al.  Sublingual immunotherapy not effective in house dust mite–allergic children in primary care , 2012, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[82]  A. Linneberg,et al.  Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality. , 2012, The Journal of allergy and clinical immunology.

[83]  S. Durham,et al.  Rhinitis , sinusitis , and upper airway disease SQ-standardized sublingual grass immunotherapy : Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial , 2012 .

[84]  C. Rondón,et al.  Rhinitis, sinusitis, and upper airway disease Nasal allergen provocation test with multiple aeroallergens detects polysensitization in local allergic rhinitis , 2016 .

[85]  G. Liss,et al.  Immediate and delayed-onset systemic reactions after subcutaneous immunotherapy injections: ACAAI/AAAAI surveillance study of subcutaneous immunotherapy: year 2. , 2011, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[86]  P. Keith,et al.  Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen. , 2011, Allergy and asthma proceedings.

[87]  D. Larenas-Linnemann,et al.  Maintenance dosing for sublingual immunotherapy by prominent European allergen manufacturers expressed in bioequivalent allergy units. , 2011, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[88]  C. Rhee,et al.  Sublingual immunotherapy in allergic rhinitis , 2011, Asia Pacific allergy.

[89]  E. Valovirta,et al.  Design and recruitment for the GAP trial, investigating the preventive effect on asthma development of an SQ-standardized grass allergy immunotherapy tablet in children with grass pollen-induced allergic rhinoconjunctivitis. , 2011, Clinical therapeutics.

[90]  P. Demoly,et al.  Dosing and efficacy in specific immunotherapy , 2011, Allergy.

[91]  G. Stingl,et al.  Malignancy and Specific Allergen Immunotherapy: The Results of a Case Series , 2011, International Archives of Allergy and Immunology.

[92]  G. Passalacqua,et al.  Adherence to sublingual immunotherapy in preschool children , 2011, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[93]  S. Durham,et al.  Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. , 2011, The Journal of allergy and clinical immunology.

[94]  M. Blaiss,et al.  Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. , 2011, The Journal of allergy and clinical immunology.

[95]  Michelle E. Kho,et al.  AGREE II: advancing guideline development, reporting and evaluation in health care , 2010, Canadian Medical Association Journal.

[96]  F. Frati,et al.  Specific immunotherapy by the sublingual route for respiratory allergy , 2010, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.

[97]  L. Bielory,et al.  The epidemiology of ocular and nasal allergy in the United States, 1988-1994. , 2010, The Journal of allergy and clinical immunology.

[98]  S. Halken,et al.  Five‐grass pollen 300IR SLIT tablets: efficacy and safety in children and adolescents , 2010, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[99]  H. Riechelmann,et al.  Efficacy and Safety of a Glutaraldehyde-Modified House Dust Mite Extract in Allergic Rhinitis , 2010, American journal of rhinology & allergy.

[100]  Holger J Schünemann,et al.  Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. , 2010, The Journal of allergy and clinical immunology.

[101]  A. Sheikh,et al.  House dust mite avoidance measures for perennial allergic rhinitis. , 2010, The Cochrane database of systematic reviews.

[102]  G. Passalacqua,et al.  Adherence issues related to sublingual immunotherapy as perceived by allergists , 2010, Patient preference and adherence.

[103]  L. Klimek,et al.  Safety of a rush immunotherapy build-up schedule with depigmented polymerized allergen extracts. , 2010, Allergy and asthma proceedings.

[104]  G. Pajno,et al.  Sublingual immunotherapy: adherence based on timing and monitoring control visits , 2010, Allergy.

[105]  R. Lockey,et al.  Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. , 2010, The Journal of allergy and clinical immunology.

[106]  C. Rondón,et al.  Local allergic rhinitis: a new entity, characterization and further studies , 2010, Current opinion in allergy and clinical immunology.

[107]  J. Ceuppens,et al.  Immunotherapy with a modified birch pollen extract in allergic rhinoconjunctivitis: clinical and immunological effects , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[108]  L. Klimek,et al.  Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study , 2009, Allergy.

[109]  H. Nelson,et al.  Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract. , 2009, Journal of Allergy and Clinical Immunology.

[110]  H. Nelson Multiallergen immunotherapy for allergic rhinitis and asthma. , 2009, The Journal of allergy and clinical immunology.

[111]  J. Björk,et al.  There is an association between contact allergy to aluminium and persistent subcutaneous nodules in children undergoing hyposensitization therapy , 2009, Contact dermatitis.

[112]  H. R. Anderson,et al.  Global map of the prevalence of symptoms of rhinoconjunctivitis in children: The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three , 2009, Allergy.

[113]  A. Bériot-Mathiot,et al.  Cost‐effectiveness of specific immunotherapy with Grazax in allergic rhinitis co‐existing with asthma , 2008, Allergy.

[114]  H. Malling,et al.  Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. , 2008, The Journal of allergy and clinical immunology.

[115]  P. Panzner,et al.  Double-blind, placebo-controlled evaluation of grass pollen specific immunotherapy with oral drops administered sublingually or supralingually. , 2008, Respiratory medicine.

[116]  G. Viegi,et al.  Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 * , 2008, Allergy.

[117]  K. M. Pedersen,et al.  [Economic evaluation of a tablet-based vaccination against hay fever in Denmark]. , 2008, Ugeskrift for laeger.

[118]  M. Di Gioacchino,et al.  Comparison of costs of sublingual immunotherapy and drug treatment in grass-pollen induced allergy: results from the SIMAP database study , 2008, Current medical research and opinion.

[119]  H. Malling,et al.  Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. , 2007, The Journal of allergy and clinical immunology.

[120]  S. Sicherer,et al.  Immunotherapy With a Ragweed-Toll-Like Receptor 9 Agonist Vaccine for Allergic Rhinitis , 2007, Pediatrics.

[121]  S. Spector,et al.  Allergen immunotherapy: a practice parameter third update. , 2007, The Journal of allergy and clinical immunology.

[122]  A. Sheikh,et al.  Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study. , 2007, The Journal of allergy and clinical immunology.

[123]  E. Valovirta,et al.  Specific immunotherapy has long‐term preventive effect of seasonal and perennial asthma: 10‐year follow‐up on the PAT study , 2007, Allergy.

[124]  B. García,et al.  Double‐blind, placebo‐controlled study of Alternaria alternata immunotherapy: Clinical efficacy and safety , 2007, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[125]  C. Bachert,et al.  Cost‐effectiveness of grass allergen tablet (GRAZAX®) for the prevention of seasonal grass pollen induced rhinoconjunctivitis – a Northern European perspective , 2007, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[126]  H. Keiding,et al.  A cost-effectiveness analysis of immunotherapy with SQ allergen extract for patients with seasonal allergic rhinoconjunctivitis in selected European countries , 2007, Current medical research and opinion.

[127]  E. Fernández‐Caldas,et al.  Safety of immunotherapy with therapeutic vaccines containing depigmented and polymerized allergen extracts , 2007, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[128]  D. Charpin,et al.  Immunotherapy with an Aluminum Hydroxide-Adsorbed Juniperus ashei Foreign Pollen Extract in Seasonal Indigenous Cypress Pollen Rhinoconjunctivitis , 2007, International Archives of Allergy and Immunology.

[129]  G. Canonica,et al.  Economic evaluation of sublingual immunotherapy vs symptomatic treatment in adults with pollen-induced respiratory allergy: the Sublingual Immunotherapy Pollen Allergy Italy (SPAI) study. , 2006, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[130]  R. Coffman,et al.  Immunotherapy With a Ragweed-Toll-Like Receptor 9 Agonist Vaccine for Allergic Rhinitis , 2007, Pediatrics.

[131]  E. Valovirta,et al.  Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children , 2006, Allergy.

[132]  O. Kalayci,et al.  The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis , 2006, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[133]  P. Falagiani,et al.  Clinical efficacy and safety of preseasonal sublingual immunotherapy with grass pollen carbamylated allergoid in rhinitic patients. A double-blind, placebo-controlled study. , 2006, Allergologia et immunopathologia.

[134]  S. Durham,et al.  Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. , 2006, Journal of Allergy and Clinical Immunology.

[135]  G. Canonica,et al.  Randomized double‐blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites , 2006, Allergy.

[136]  L. Cox,et al.  Sublingual immunotherapy: a comprehensive review. , 2006, The Journal of allergy and clinical immunology.

[137]  William H. Yang,et al.  Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. , 2006, The Journal of allergy and clinical immunology.

[138]  R. Ariano,et al.  Pharmacoeconomics of allergen immunotherapy compared with symptomatic drug treatment in patients with allergic rhinitis and asthma. , 2006, Allergy and asthma proceedings.

[139]  L. Fonacier,et al.  Safety of Allergenic Immunotherapy in Systemic Lupus Erythematosus , 2006 .

[140]  R. Dahl,et al.  Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis , 2006, Allergy.

[141]  P. Eng,et al.  Twelve‐year follow‐up after discontinuation of preseasonal grass pollen immunotherapy in childhood , 2006, Allergy.

[142]  S. Durham,et al.  Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. , 2006, The Journal of allergy and clinical immunology.

[143]  E. Fernández‐Caldas,et al.  Safety of an Ultra-Rush Immunotherapy Build-Up Schedule with Therapeutic Vaccines Containing Depigmented and Polymerized Allergen Extracts , 2006, International Archives of Allergy and Immunology.

[144]  O. Cromwell,et al.  Clinical effects of specific immunotherapy: a two-year double-blind, placebo-controlled study with a one year follow-up. , 2005, Prilozi.

[145]  M. Reaño Martos,et al.  Vasculitis during immunotherapy treatment in a patient with allergy to Cupressus arizonica. , 2005, Allergologia et immunopathologia.

[146]  C. Giaquinto,et al.  Cost effectiveness of sublingual immunotherapy in children with allergic rhinitis and asthma. , 2005, European annals of allergy and clinical immunology.

[147]  M. Jutel,et al.  Allergen-specific immunotherapy with recombinant grass pollen allergens. , 2005, The Journal of allergy and clinical immunology.

[148]  S. La Grutta,et al.  Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years. , 2005, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[149]  A. Narkus,et al.  Efficacy and safety of preseasonal‐specific immunotherapy with an aluminium‐adsorbed six‐grass pollen allergoid , 2005, Allergy.

[150]  G. Passalacqua,et al.  Post‐marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[151]  G. Passalacqua,et al.  Safety of sublingual immunotherapy with a monomeric allergoid in very young children , 2005, Allergy.

[152]  P. Keith,et al.  Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis. , 2004, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[153]  T. Keil,et al.  The co‐seasonal application of anti‐IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children , 2004, Allergy.

[154]  G. Liss,et al.  Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. , 2004, The Journal of allergy and clinical immunology.

[155]  T. Holland-Letz,et al.  Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double‐blind placebo‐controlled study , 2004, Allergy.

[156]  J. Kelso The rate of systemic reactions to immunotherapy injections is the same whether or not the dose is reduced after a local reaction. , 2004, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[157]  S. La Grutta,et al.  Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate , 2003, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[158]  S. Woroniecki,et al.  Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MPL) for children and adolescents. , 2003, Allergologia et immunopathologia.

[159]  A. Frew,et al.  Usefulness of specific immunotherapy in patients with severe perennial allergic rhinitis induced by house dust mite: a double‐blind, randomized, placebo‐controlled trial , 2003, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[160]  R. Gerth van Wijk,et al.  Evaluation of impermeable covers for bedding in patients with allergic rhinitis. , 2003, The New England journal of medicine.

[161]  A. Barbato,et al.  Effects on inflammation parameters of a double‐blind, placebo controlled one‐year course of SLIT in children monosensitized to mites , 2003, Allergy.

[162]  G. Roberts,et al.  Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma. , 2003, The Journal of allergy and clinical immunology.

[163]  G. Feder,et al.  Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project , 2003, Quality & safety in health care.

[164]  K. J. Drachenberg,et al.  Kurzzeit-Immuntherapie mit Baumpollen-Allergoiden und dem Adjuvans Monophosphoryl Lipid-A: Ergebnisse einer randomisierten, doppelblinden, plazebokontrollierten Multicenterstudie , 2002 .

[165]  H. Malling,et al.  The safety and efficacy of subcutaneous birch pollen immunotherapy – a one‐year, randomised, double‐blind, placebo‐controlled study , 2002, Allergy. European Journal of Allergy and Clinical Immunology.

[166]  R. Lockey,et al.  Systemic reactions and fatalities associated with allergen immunotherapy. , 2001, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[167]  I. Barlan,et al.  Efficacy of sublingual immunotherapy in children with asthma and rhinitis: A double‐blind, placebo‐controlled study , 2001, Pediatric pulmonology.

[168]  F. Horak,et al.  A well‐tolerated grass pollen‐specific allergy vaccine containing
a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections , 2001, Allergy.

[169]  C. Caffarelli,et al.  Preseasonal local allergoid immunotherapy to grass pollen in children: a double‐blind, placebo‐controlled, randomized trial , 2000, Allergy.

[170]  H. Malling Minimising the Risks of Allergen-Specific Injection Immunotherapy , 2000, Drug safety.

[171]  A. Kapp,et al.  Aluminium‐induced granulomas after inaccurate intradermal hyposensitization injections of aluminium‐adsorbed depot preparations , 2000, Allergy.

[172]  Y. Hari,et al.  Reduction of side‐effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine:a double‐blind, placebo‐controlled trial , 2000, Allergy.

[173]  C. André,et al.  House‐dust‐mite sublingual‐swallow immunotherapy (SLIT) in perennial rhinitis: a double‐blind, placebo‐controlled study , 2000, Allergy.

[174]  S. Durham,et al.  Allergen immunotherapy: does it work and, if so, how and for how long? , 2000, Thorax.

[175]  J Bousquet,et al.  Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. , 1998, The Journal of allergy and clinical immunology.

[176]  L. Klimek,et al.  Tree‐pollen allergy is efficiently treated by short‐term immunotherapy (STI) with seven preseasonal injections of molecular standardized allergens , 1998, Allergy.

[177]  G. Canonica,et al.  Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis , 1998, The Lancet.

[178]  R. Naclerio,et al.  A double-blind study of the discontinuation of ragweed immunotherapy. , 1997, The Journal of allergy and clinical immunology.

[179]  G. Rasp,et al.  Short-term immunotherapy: a prospective, randomized, double-blind, placebo-controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis. , 1997, The Journal of allergy and clinical immunology.

[180]  T. Hirsch,et al.  Double‐blind placebo‐controlled study of sublingual immunotherapy with house dust mite extract (D. pt.) in children , 1997, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[181]  J. Tonascia,et al.  A controlled trial of immunotherapy for asthma in allergic children. , 1997, The New England journal of medicine.

[182]  C. Martínez-Cócera,et al.  A double‐blind, placebo‐controlled study of immunotherapy with grass‐pollen extract Alutard SQ during a 3–year period with initial rush immunotherapy , 1996, Allergy.

[183]  H. Malling,et al.  Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study. , 1996, The Journal of allergy and clinical immunology.

[184]  V. Feliziani,et al.  Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study. , 1995, Allergologia et immunopathologia.

[185]  D. Lang Anaphylactoid and Anaphylactic Reactions , 1995 .

[186]  E. Pastorello,et al.  A double‐blind, placebo‐controlled study of immunotherapy with an alginate‐conjugated extract of Parietaria Judaica in patients with Parietaria hay fever , 1994, Allergy.

[187]  L. Espinoza,et al.  Digital vasculitis following allergic desensitization treatment. , 1993, The Journal of rheumatology.

[188]  H. Malling Immunotherapy for mold allergy , 1992, Clinical reviews in allergy.

[189]  S. Durham,et al.  Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. , 1991, BMJ.

[190]  M. Mancino,et al.  Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. , 1990, Allergologia et immunopathologia.

[191]  J. Bousquet,et al.  Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. Systemic reactions during the rush protocol in patients suffering from asthma. , 1989, The Journal of allergy and clinical immunology.

[192]  P. Ewan,et al.  Effective hyposensitization in allergic rhinitis using a potent partially purified extract of house dust mite , 1988, Clinical allergy.

[193]  J. Bousquet,et al.  Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. I. Rush immunotherapy with allergoids and standardized orchard grass-pollen extract. , 1987, The Journal of allergy and clinical immunology.

[194]  CSM Update: Desensitising vaccines , 1986, British medical journal.

[195]  M. Nielsen,et al.  Persistent Subcutaneous Nodules in Children Hyposensitized with Aluminium‐Containing Allergen Extracts , 1985, Allergy.

[196]  L. Horwitz,et al.  Beta‐2 adrenergic blockade evaluated with epinephrine after placebo, atenolol, and nadolol , 1985, Clinical pharmacology and therapeutics.

[197]  G. Pauli,et al.  Grass Pollen Hyposensitization versus Placebo Therapy , 1981, Allergy.

[198]  R. Patterson,et al.  The safety of immunotherapy during pregnancy. , 1978, The Journal of allergy and clinical immunology.

[199]  D. Shand,et al.  A standardized isoproterenol sensitivity test. The effects of sinus arrhythmia, atropine, and propranolol. , 1972, Archives of internal medicine.

[200]  R. Settipane,et al.  Allergic rhinitis , 2005, Rhinology and Anterior Skull Base Surgery.

[201]  M. Rank,et al.  American Academy of Allergy, Asthma Immunology membership experience with allergen immunotherapy safety in patients with specific medical conditions. , 2016, Allergy and asthma proceedings.

[202]  M. Larché,et al.  Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. , 2013, The Journal of allergy and clinical immunology.

[203]  T. Kündig,et al.  Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation study. , 2012, The Journal of allergy and clinical immunology.

[204]  J. Brecht,et al.  Economic Evaluation of Specific Immunotherapy Versus Symptomatic Treatment of Allergic Rhinitis in Germany , 2012, PharmacoEconomics.

[205]  S. Durham,et al.  Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. , 2010, The Journal of allergy and clinical immunology.

[206]  R. Mitchell Burden of allergic rhinitis: Results from the Pediatric Allergies in America survey , 2010 .

[207]  L. Cox,et al.  Allergen immunotherapy and health care cost benefits for children with allergic rhinitis: a large-scale, retrospective, matched cohort study. , 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[208]  L. Klimek,et al.  Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. , 2009, The Journal of allergy and clinical immunology.

[209]  P. Kuna,et al.  Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. , 2009, The Journal of allergy and clinical immunology.

[210]  O. Rodríguez Santos [Sublingual immunotherapy in allergic rhinitis and asthma in 2-5 year-old children sensitized to mites]. , 2008, Revista alergia Mexico.

[211]  E. Meltzer,et al.  Allergy immunotherapy among Medicaid-enrolled children with allergic rhinitis: patterns of care, resource use, and costs. , 2008, The Journal of allergy and clinical immunology.

[212]  A. Graham,et al.  Evidence-Based Medicine: Levels of Evidence and Grades of Recommendation , 2007 .

[213]  J. Algorta,et al.  Biological standardization and maximum tolerated dose estimation of an Alternaria alternata allergenic extract. , 2006, Journal of investigational allergology & clinical immunology.

[214]  G. Liss,et al.  Evaluation of near-fatal reactions to allergen immunotherapy injections. , 2006, The Journal of allergy and clinical immunology.

[215]  Vicki Seyfert-Margolis,et al.  Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. , 2006, The Journal of allergy and clinical immunology.

[216]  R. Dahl,et al.  Health-economic analyses of subcutaneous specific immunotherapy for grass pollen and mite allergy. , 2005, Allergologia et immunopathologia.

[217]  E. Enrique,et al.  Double-blind, placebo-controlled study of immunotherapy with Parietaria judaica: clinical efficacy and tolerance. , 2005, Journal of investigational allergology & clinical immunology.

[218]  F. Cluzeau,et al.  Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project , 2003 .

[219]  N. Klazinga,et al.  Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project [AGREE] , 2003 .

[220]  R. Panzani,et al.  Efficacy of sublingual specific immunotherapy in Cupressaceae allergy using an extract of Cupressus arizonica. A double blind study. , 2001, Allergologia et immunopathologia.

[221]  S. Durham,et al.  Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. , 2001, The Journal of allergy and clinical immunology.

[222]  M. Abramson,et al.  Ragweed immunotherapy in adult asthma. , 1996, The New England journal of medicine.

[223]  J. Hébert,et al.  Allergic rhinitis to ragweed pollen. I. Reassessment of the effects of immunotherapy on cellular and humoral responses. , 1992, The Journal of allergy and clinical immunology.